The renin-angiotensin-aldosterone-system (RAAS) has been implicated in the association between hypertension and T2DM [12,13], and most treatment guidelines recommend the use of an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin II type 1 receptor blocker (ARB) in these patients, especially in the presence of proteinuria or microalbuminuria [13,14]. Here, ACE is linked to Hypertension.